公开(公告)号：US20240360214A1

公开(公告)日：2024-10-31

申请号：US18639118

申请日：2024-04-18

申请人： PFIZER INC.

发明人： James Reasoner APGAR ,  Wei CAO ,  Timothy HEMESATH ,  Christina Lynn O'HALLORAN ,  Lan WU ,  Ming ZHU

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC分类号： C07K16/2803 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/31 ,  C07K2317/76 ,  C07K2317/92

摘要： The invention is directed to Anti-LILRB1 and anti-LILRB2 bispecific antibodies, anti-LILRB1 antibodies, and anti-LILRB2 antibodies, their uses and pharmaceutical compositions thereof.

公开(公告)号：US20240325513A1

公开(公告)日：2024-10-03

申请号：US18596916

申请日：2024-03-06

申请人： Pfizer Inc.

发明人： Robert G.K. Donald ,  Rosalind Pan

IPC分类号： A61K39/108 ,  A61K39/00 ,  A61K39/385 ,  A61P31/04 ,  A61P37/04

CPC分类号： A61K39/0258 ,  A61K39/0266 ,  A61K39/385 ,  A61P31/04 ,  A61P37/04 ,  A61K2039/6031

摘要： This invention provides a polypeptide derived from E. coli or a fragment thereof, including compositions and methods thereof. In one embodiment, the compositions comprise a polypeptide derived from E. coli or a fragment thereof, and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides or conjugates thereof. In a further aspect, the compositions further comprise modified O-polysaccharide molecules derived from Klebsiella pneumoniae or conjugates thereof.

公开(公告)号：US12077533B2

公开(公告)日：2024-09-03

申请号：US17393463

申请日：2021-08-04

申请人： Pfizer Inc.

发明人： Atli Thorarensen ,  Matthew Frank Brown ,  Agustin Casimiro-Garcia ,  Ye Che ,  Jotham Wadsworth Coe ,  Mark Edward Flanagan ,  Adam Matthew Gilbert ,  Matthew Merrill Hayward ,  Jonathan David Langille ,  Justin Ian Montgomery ,  Jean-Baptiste Telliez ,  Rayomand Jal Unwalla ,  John I Trujillo

IPC分类号： A61K31/4523 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/10 ,  C07D498/04

CPC分类号： C07D471/04 ,  A61K31/4523 ,  C07D471/08 ,  C07D487/04 ,  C07D487/10 ,  C07D498/04

摘要： The present invention provides a method for treating alopecia using certain pharmaceutically active pyrrolo[2,3-d]pyrimidinyl acrylamides having the structure:




or a pharmaceutically acceptable salt thereof, as set forth in the Description.

公开(公告)号：US12049465B2

公开(公告)日：2024-07-30

申请号：US17886807

申请日：2022-08-12

申请人： PFIZER INC.

发明人： Thomas Allen Chappie ,  Nandini Chaturbhai Patel ,  Patrick Robert Verhoest ,  Christopher John Helal ,  Simone Sciabola ,  Erik Alphie LaChapelle ,  Travis T. Wager ,  Ramalakshmi Yegna Chandrasekaran

IPC分类号： C07D471/14 ,  C07D471/22 ,  C07D487/04 ,  C07D487/14 ,  C07D491/147 ,  C07D491/22 ,  C07D498/22 ,  C07D513/14 ,  C07D519/00

CPC分类号： C07D471/14 ,  C07D471/22 ,  C07D487/04 ,  C07D487/14 ,  C07D491/147 ,  C07D491/22 ,  C07D498/22 ,  C07D513/14 ,  C07D519/00

摘要： The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.

公开(公告)号：US20240216495A1

公开(公告)日：2024-07-04

申请号：US18446883

申请日：2023-08-09

申请人： Pfizer Inc.

发明人： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Robert G.K. Donald ,  Michael James Flint ,  Nicholas Randolph Everard Kitchin ,  Justin Keith Moran ,  Louise Pedneault ,  Michael W. Pride ,  Mark Edward Ruppen ,  Christopher Frederick Webber

IPC分类号： A61K39/08 ,  A61K9/19 ,  A61K39/00

CPC分类号： A61K39/08 ,  A61K9/19 ,  A61K2039/545

摘要： In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.

公开(公告)号：US20240207257A1

公开(公告)日：2024-06-27

申请号：US18555058

申请日：2022-04-14

申请人： IDEAYA BIOSCIENCES, INC. ,  PFIZER, INC.

发明人： Matthew Anthony MAURER ,  Michael Gabriel O'QUIGLEY ,  Jaymes HOLLAND ,  Sarah Shwu-Kuan Jaw-Tsai ,  Julie Hambleton ,  MAI HOPE LE

IPC分类号： A61K31/497 ,  A61K31/4184 ,  A61P35/00

CPC分类号： A61K31/497 ,  A61K31/4184 ,  A61P35/00

摘要： Provided herein is a combination therapy and methods of using such combination therapy to treat diseases or disorders associated with PKC and MEK.

公开(公告)号：US20240197703A1

公开(公告)日：2024-06-20

申请号：US18144737

申请日：2023-05-08

申请人： PFIZER INC.

发明人： Joyann Barber ,  Sujin Cho-Schultz ,  Matthew L. Del Bel ,  Rebecca Anne Gallego ,  Mingying He ,  Mehran Jalaie ,  Robert Steven Kania ,  Michele Ann McTigue ,  Sajiv Krishnan Nair ,  Anne-Marie Dechert Schmitt ,  Jamison Bryce Tuttle ,  Dahui Zhou ,  Ru Zhou

IPC分类号： A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

CPC分类号： A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

摘要： This invention relates to compounds of general Formula I






and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20240181071A1

公开(公告)日：2024-06-06

申请号：US18492055

申请日：2023-10-23

申请人： Pfizer Inc.

发明人： Andrea Therese HOOPER ,  Kimberly Ann MARQUETTE ,  Chakrapani SUBRAMANYAM ,  Hans-Peter GERBER ,  Chad Michael MAY

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K16/18

CPC分类号： A61K47/6803 ,  A61K47/6843 ,  A61P35/00 ,  C07K16/18 ,  A61K38/08 ,  A61K47/6811

摘要： The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.

公开(公告)号：US20240181028A1

公开(公告)日：2024-06-06

申请号：US18513738

申请日：2023-11-20

申请人： Pfizer Inc.

发明人： Catherine Alex ,  Annaliesa Sybil Anderson ,  Bishwa Raj Bhetuwal ,  Zecheng Chen ,  Kaushik Dutta ,  Caitlyn Gallagher ,  Jianxin Gu ,  Isis Kanevsky ,  Jin-Hwan Kim ,  Justin Keith Moran ,  Suddham Singh ,  Naveen Surendran ,  Abhishek Ravindra Vartak ,  YuYing Yang

IPC分类号： A61K39/09 ,  A61K47/64

CPC分类号： A61K39/092 ,  A61K47/646

摘要： The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in Prevnar, Synflorix and/or Prevnar 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

公开(公告)号：US20240180906A1

公开(公告)日：2024-06-06

申请号：US18283634

申请日：2022-03-21

申请人： Pfizer Inc. ,  Astellas Pharma Inc.

发明人： Akos Gabor Czibere ,  Dana Ann Kennedy

IPC分类号： A61K31/5025 ,  A61K31/4166 ,  A61K45/06

CPC分类号： A61K31/5025 ,  A61K31/4166 ,  A61K45/06

摘要： This invention relates to combination therapies comprising talazoparib, or a pharmaceutically acceptable salt thereof, and an anti-androgen, or a pharmaceutically acceptable salt thereof, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses for the treatment of metastatic castration-sensitive prostate cancer in subjects identified as having at least one DNA damage repair gene mutation.